Zacks Investment Research upgraded shares of LANNETT INC (LCI) from NEUTRAL to OUTPERFORM on February 08, 2013, with a target price of $7.70.
Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on LANNETT INC (LCI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment